Qwell Pharmaceuticals, Backed by Arch, Raises $7M for New Cancer, Inflammation Drugs

1/6/09Follow @xconomy

(Page 2 of 2)

with other companies aiming for that target such as Seattle-based Calistoga Pharmaceuticals, San Diego-based Intellikine, South San Francisco-based Exelixis, and Swiss drug giant Novartis.

The intellectual property license to develop Qwell’s drugs comes from the Clayton Foundation for Research, a Houston-based foundation that financed Gutterman’s work, Gillis says. The Clayton Foundation has also provided non-dilutive capital to support the company, he says.

When describing Qwell’s potential, Gillis made an analogy to one of the biggest-selling cancer drugs ever, the chemotherapy agent paclitaxel (Taxol). This product, which exceeded $1.6 billion in peak annual sales for Bristol-Myers Squibb in 2000 before it lost patent protection, was famously derived from the bark of the Pacific yew tree. Years later, chemists were able to make it more efficiently (and make it environmentally-friendly) through synthetic methods.

Qwell’s drug candidates, Gillis says, work differently from paclitaxel, which works by disrupting rapid-fire cell division that is a hallmark of cancer cells. He wouldn’t say what mechanism the new drugs use, or what targets they are engineered to hit on cells. He did say they have novel chemical structures, and that they are more soluble in the body than paclitaxel, which is notoriously harsh and has to be mixed with a castor-oil type solution that causes side effects.

So far, Qwell’s scientists have shown an ability to extract and purify the drug efficiently from plant sources. Batches have already been made that meet FDA standards for Good Manufacturing Practices, and it is likely that chemists will be able to make them even more efficiently through synthetic means, like the Bristol-Myers drug, Gillis says. “We should have far less of a problem producing these molecules than folks did for the early clinical trials of Taxol,” Gillis says.

Qwell is staying lean for the time being with just two full-time employees and one part-timer, with most of the lab work being done by contractors, Gillis says. The company currently has three job postings online, for a director of clinical research, a director of quality and regulatory affairs, and a pre-clinical toxicology consultant.

Besides his longstanding relationship with Gillis, Gutterman has a track record as an inventor. He played a key role in the early work on developing the first approved form of interferon alpha therapy for Kaposi’s sarcoma, a rare form of cancer.

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.